We’d love to hear your feedback on this activity. It helps us to continually improve our products.
We were delighted to speak to Professor Carmelo Rizzari, President of the European Society of Paediatric Oncology (SIOP Europe), who summarized the structure, organisation and goals of the society, and why the Annual Meeting took place virtually in March 2022. Questions Please summarize the organization, structure and remits of SIOPE? (01:00-03:09) Why did the SIOP […]
Professor Benjamin A Weinberg (Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA) summarises key data from pivotal studies in colorectal cancer that were presented at the ASCO Gastrointestinal Cancers Symposium 2022. GALAXY study in CIRCULATE-Japan abstract: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.009 Clinical trial information: jRCT1031200006 RESPECT study abstract: https://meetings.asco.org/abstracts-presentations/204531 Clinical Trial Registration Number: UMIN000008866 GERCOR NIPICOL study abstract: […]
Dr Kim Chi (The University of British Columbia, Vancouver, BC, Canada) summarises the first results of the phase 3 MAGNITUDE (NCT03748641) study of niraparib with abiraterone acetate and prednisone as first-line therapy in patients with metastatic castration-resistant prostate cancer with and without homologous recombination repair gene alterations. Abstract: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.012 Questions What is […]
touchONCOLOGY were thrilled to speak to Editorial Board member Professor John Marshall (Medstar Georgetown University Hospital, Washington, DC, USA) to summarise the latest developments and data from the ASCO Gastrointestinal Cancers Symposium 2022. The phase III CheckMate 577 Study (NCT03044613): https://meetings.asco.org/abstracts-presentations/204867 KEYNOTE-062 (NCT02494583): https://meetings.asco.org/abstracts-presentations/204515 JCOG NExT study (UMIN000014795): https://meetings.asco.org/abstracts-presentations/204882 Questions: Could you give us a […]
touchONCOLOGY were thrilled to speak to Editorial Board member Professor John Marshall (Medstar Georgetown University Hospital, Washington, DC, USA) to summarise the latest developments and data from the ASCO Gastrointestinal Cancers Symposium 2022. The phase III CheckMate 577 Study (NCT03044613): https://meetings.asco.org/abstracts-presentations/204867 KEYNOTE-062 (NCT02494583): https://meetings.asco.org/abstracts-presentations/204515 JCOG NExT study (UMIN000014795): https://meetings.asco.org/abstracts-presentations/204882 Questions: What have recent clinical study […]
touchONCOLOGY were thrilled to speak to Professor Marcus S Noel (Medstar Georgetown University Hospital, Washington, DC, USA) to summarise the latest developments and data from the ASCO Gastrointestinal Cancers Symposium 2022. Questions What is the rationale for the use of L-asparaginase in the treatment of pancreatic cancer? 00:22-01:00 Could […]
touchONCOLOGY were thrilled to speak to Professor Benjamin A Weinberg (Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA) to discuss the data from the TRYbeCA-1, KRYSTAL-1 and CISPD3 trials, which were presented at the ASCO Gastrointestinal Cancers Symposium 2022. Questions What are the hopes of the new drug delivery mechanism using L-asparaginase to treat […]
touchONCOLOGY caught up with Professor Angela Lamarca (Christie NHS Foundation Trust, Manchester, UK) to discuss her highlights from the Liver Cancer Summit 2022, targeted therapies for cholangiocarcinoma and some of the most important current trial data in hepatic-biliary oncology (the HIMALAYA and TOPAZ-1 studies). What were your highlights and hot topics from the Liver Cancer […]
touchONCOLOGY were joined by Dr Simon Crabb (Southampton University, UK) to discuss his presentation on the rucaparib arm of the ATLANTIS study, a randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma. Questions What is the rationale for the use of PARP inhibitors in the […]
Get the latest clinical insights from touchONCOLOGY